Summary
For many years the varying methods of price control of medicines by national governments in the European Community (and elsewhere) have resulted in wide variations in prices, Parallel traders buy products in low pricing Community countries and sell them, generally relabelled or repackaged, in high pricing Community countries, This practice diverts sales revenue and profits from the manufacturers to the traders, distributors, pharmacists and, in some measure, to the sickness funds and to some patients, While parallel trade appeals to those who gain financially, its basis is a market distortion that poses a significant threat to the future of the research—based pharmaceutical industry
Similar content being viewed by others
References
Diener F. Pharmazeutische Zeitung 40: 2631–2638, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, I. Is Parallel Trade in Medicines Compatible with the Single European Market?. Pharmacoeconomics 1 (Suppl 1), 70–76 (1992). https://doi.org/10.2165/00019053-199200011-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199200011-00015